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Available online 14 March 2008Reproductive hormones have been demonstrated to modulate both gap and tight junction protein expression in
the ovary and other reproductive tissues, however the effects of changes in reproductive hormones on the
selective permeability of the blood-brain barrier (BBB) remain unclear. Age-related declines in BBB integrity
correlate with the loss of serum sex steroids and increase in gonadotropins with menopause/andropause. To
examine theeffectof reproductive senescenceonBBBpermeabilityandgapand tight junctionprotein expression/
localization, female mice at 3 months of age were either sham operated (normal serum E2 and gonadotropins),
ovariectomized (low serum E2 and high serum gonadotropins) or ovariectomized and treated with the GnRH
agonist leuprolide acetate (low serum E2 and gonadotropins). Ovariectomy induced a 2.2-fold increase in Evan's
blue dye extravasation into the brain. The expression and localization of the cytoplasmic membrane-associated
tight junction protein zona occludens 1 (ZO-1) inmicrovessels was not altered among groups indicating that the
increased paracellular permeability was not due to changes in this tight junction protein. However, ovariectomy
induced a redistribution of the gap junction protein connexin-43 (Cx43) such that immunoreactivity relocalized
from along the extracellular microvascular endothelium to become associatedwith endothelial cells. An increase
in Cx43 expression in themouse brain following ovariectomywas suppressed in ovariectomized animals treated
with leuprolide acetate, indicating that serum gonadotropins rather than sex steroids were modulating Cx43
expression. These results suggest that elevated serum gonadotropins following reproductive senescence
may be one possible cause of the loss of selective permeability of the BBB at this time. Furthermore, these
ﬁndings implicate Cx43 in mediating changes in BBB permeability, and serum gonadotropins in the
cerebropathophysiology of age-related neurodegenerative diseases such as stroke and Alzheimer's disease.
© 2008 Elsevier B.V. All rights reserved.Keywords:
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The blood-brain barrier (BBB) maintains brain homeostasis by
limiting entry of substances to the central nervous system [1] through
interaction of transmembrane and intracellular proteins that make up
endothelial cell tight junctions and gap junctions. Although complex,
tight junction proteins such as zona occludens 1 (ZO-1) and ZO-2,
occludin and claudin-5, and gap junction proteins such as connexin-r’s Association and Veterans
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l rights reserved.43 (Cx43), Cx45, Cx32 and Cx26 between endothelial cells maintain
the selective permeability of the BBB [2]. The importance of gap
junction proteins is indicated by the neurodevelopmental and deﬁcits
observed in Cx knockout mice [3]. Therefore, the identiﬁcation of
factors regulating the expression and function of junctional proteins is
crucial for understanding the maintenance of BBB function during
health and alterations during disease.
Failure of the BBB leads to neuroinﬂammatory diseases such as
encephalitis and meningitis [4], and is associated with neurological
diseases such as stroke, cerebral amyloid angiopathy and Alzheimer's
disease (AD; [5–9]). The selective permeability of the BBB appears to be
compromised during the normal course of aging [10] and numerous
associated changes have been reported in the aging cerebrovasculature
includingdecreasedmicrovasculardensity, lossof endothelium, increased
tortuosity, twisted/string vessels, fragmentation of the microvasculature,
loss of the ﬁne perivascular neural plexus, and lumpy vessels. Such
changes are far more pronounced in the neurodegenerative condition of
Table 1
Summary of animals for hormonal modulation experiments
Group
number
Group
name
Gonadotropin
level c.f.
control
Estrogen level
c.f. control
Number
of mice
Age at
euthanasia
(month)
1 Sham OVX+vehicle Normal Normal 9 16
2 OVX+vehicle High Low 6 16
3 OVX+leuprolide Low Low 6 16
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signiﬁcantly greater than in control brain [12].
The incidence of neuroinﬂammatory diseases is increased during
development and senescence, and correlates with the marked hor-
monal changes that occur during these times. Interestingly, dysregula-
tion of the expression of gap junction and tight junction proteins, and
alterations in paracellular permeability and junctional communica-
tion, aremediated by reproductive hormones. In particular, it has been
reported that sex steroids canmodulate changes in BBBpermeability of
female rats [13]. In this context, luteinizing hormone (LH), which
becomes markedly elevated with reproductive senescence, has been
demonstrated to potently down-regulate, via PKA/MAPK signaling
pathways, the expression of Cx43 in large preovulatory follicles, theca
cells and follicles undergoing atresia [14–18]. The developmental
hormone, human chorionic gonadotropin (hCG), which has 83%
homology to LH and binds the same receptor (LH/hCG receptor), also
potently decreases Cx43 expression and morphological gap junctions
in human myometrial smooth muscle cells [19]. In addition, LH de-
creases Cx43 expression and endometrial thickness in the human
endometrium [20], promotes germinal vesicle breakdown possibly
through a reduction of Cx43 in cumulus cells [21] and induces a
decrease in the integrity of gap junctions in apoptotic humangranulosa
cells [22]. Recently, LH was shown to induce oocyte maturation via the
interruption of cell-to-cell communicationwithin the ovarian follicle, a
process possibly mediated by the phosphorylation of Cx43 [23].
The decline in serum sex steroidswith reproductive senescencemay
also alter BBB permeability. Hypothalamic Cx43 expression has been
demonstrated to be regulated by steroid hormones in a brain-region-
speciﬁc and sexually dimorphic manner in rats [24]. 17β-estradiol has
been shown to modulate the expression of occludin, transendothelial
resistance and paracellular permeability in human vascular endothelial
cells [25] and human cervical epithelial cells [26]. Strong expression of
endometrial Cx43 and Cx26 has been correlated with high serum
concentrations of 17β-estradiol and progesterone, respectively, while
gonadotropin-releasing hormone (GnRH) agonist treatment suppresses
the expression of both connexins [27]. There also is evidence that ZO-1
expression is regulated by reproductive hormones [28].
Surprisingly, the role of reproductive hormones in the expression of
these proteins required for the maintenance of the BBB is largely
unexplored. Due to the facts that 1) gonadotropins become markedly
elevated with menopause [29,30]/andropause [31], and 2) receptors
for LH/hCG have been localized to endothelial cells and smoothmuscle
cells of the vasculature [32,33] and to neuronal cells [34–38], we
hypothesized that menopause-related changes in serum reproductive
hormones may alter the expression and/or function of tight and gap
junctional proteins leading to the deterioration of the BBB associated
with aging and neurodegenerative diseases. We report that ovariect-
omy increases the permeability of the BBB in young mice, and that
changes in the expression and distribution of the gap junction protein
Cx43 are mediated by gonadotropins. Thus, elevated serum gonado-
tropins following reproductive senescencemay be one explanation for
the loss of the selective permeability of the BBB with aging.
2. Materials and methods
2.1. Animals
Female B6/SJL mice (~3months; Jackson Laboratory, Bar Harbor, Maine) and Tg2576
mice (Taconic, Germantown, New York) housed in the Animal Resource Center at Case
Western Reserve University, Cleveland, OH were provided ad libitum access to food and
water and maintained on a 12 h light/dark cycle. All procedures performed on animals
were reviewed and approved by the Animal Resource Center of Case Western Reserve
University, Cleveland, OH.
2.2. Experiment 1
Young female B6/SJL mice were either ovariectomized (n=5) or left intact (n=5).
Young mice were used to avoid possible complications that might arise from post-
estrous animals where the BBB might already be compromised or where other com-pensatory mechanisms might complicate data interpretation. Vaginal smears were
performed post-surgery to examine the histology of epithelial cells to conﬁrm that
ovariectomy was successful. Two weeks after surgery, prior to sacriﬁce, mice were
injected in the tail veinwith a 2% Evan's blue dye solution to examine BBB permeability.
2.2.1. Quantitation of BBB integrity
The integrity of the BBB was assessed in female B6/SJL mice by a quantitative assay
of Evan's blue dye (Sigma, St. Louis, MO). A 2% Evan's blue dye in saline solution was
injected via the tail vein of anesthetized mice (4 ml/kg/mouse) 1 h prior to sacriﬁce.
Animals were then transcardially perfused with phosphate buffered saline (PBS; Gibco,
pH 7.4), the animals decapitated, brains removed and the cerebral hemispheres
separated. One hemisphere was frozen, while the other was dropped ﬁxed in
methacarn. The frozen hemisphere was later homogenized in 400 ml of dimethyl
formamide (Sigma, St. Louis, MO) and incubated for 72 h in a 50 °C water bath. The
samples were then centrifuged at 1500 g for 10 min and the supernatant was analyzed
at 620 nm using a spectrophotometer. Results were calculated as µM of Evan's blue dye
per hemisphere as compared to a standard Evans blue dye curve. The other hemisphere
of tissue was processed for histological analysis (as described below).
2.3. Experiment 2
Tg2576 mice at ~7.5 months of age were either bilaterally sham ovariectomized,
ovariectomized or ovariectomized and treated with leuprolide acetate for 9 months (until
~16.5 months of age). Ovariectomizedmice were left untreated or injectedwith leuprolide
acetate. Table 1 summarizes the experimental design and predicted effects of each treat-
ment on blood hormone levels. In the ovariectomized vehicle group, blood LH and FSH
levels becomeelevatedwhileestrogen levelsdecline; in theovariectomizedplus leuprolide-
treated group, blood LH, FSH and estrogen levels all decline. This experimental design
differentiates betweenwhetherend-point changesaredue to sex steroidsor gonadotropins.
2.3.1. GnRH agonist treatment
Leuprolide acetate, a well-known GnRH agonist (Lupron Depot, TAP Pharmaceu-
ticals Inc., Lake Forest) was used for the experiments. Leuprolide acetate is a synthetic
GnRH agonist that lowers LH/FSH levels by desensitizing GnRH receptor signaling that
subsequently leads to decreased LH/FSH secretion and a decrease in the serum
concentration of sex steroids. Animals were injected intramuscularly with vehicle or
leuprolide acetate (1.5 mg/kg) biweekly during the ﬁrst month and monthly thereafter
up to 9 months. Leuprolide acetate was mixed with a diluent in a pre-ﬁlled dual-
chamber syringe containing sterile lyophilized microspheres to form a suspension.
Leuprolide is gradually released from microspheres over a 4-week period. Continuous
treatment produces initial stimulation of the pituitary and an increase in blood
gonadotropins, followed by a suppression of blood gonadotropins and sex steroids to
castrate/post-menopausal levels within ~1 week. In females, both ovarian estrogen and
androgen syntheses are inhibited.
2.3.2. Tissue collection
Blood was collected from B6/SJL mice pre-treatment and at 14 days post-surgery
from an orbital sinus after mice were anesthetized with an IP injection of mouse
anesthesia cocktail (0.1 ml/25 g body weight, containing ketamine HCl (9 mg/ml);
xylazine HCl (1.7 mg/ml); acepromazine (0.3 mg/ml) in sterile saline). Blood was
collected from Tg2576 mice at ~7.5 months of age and then again at the end of the 1st
and 3rd months from an orbital sinus after mice were anesthetized as above. The ﬁnal
blood at 9 months was collected by heart puncture. Blood was collected from animals
prior to their next dose of leuprolide acetate. Blood (100–400 µl) was collected into
EDTA-coated tubes, which were centrifuged at 1000 g for 3 min at 4 °C, followed by
centrifugation at 5000 g for 10 min prior to the collection of plasma, which was stored
at −80 °C. Mice were sacriﬁced at 16 months of age with an injection of concentrated
sodium barbital (50 µl each, 392 mg/ml, IP). Blood was collected at this time by heart
puncture, the animals were then perfused with PBS, the animals decapitated and the
brain removed from the skull. One brain hemisphere was ﬁxed in methacarn (6 parts
ethanol, 3 parts chloroform, and one part glacial acetic acid) for 24 h and then parafﬁn
embedded for immunocytochemical studies. The other brain hemisphere was frozen in
liquid nitrogen and stored at −80 °C for biochemical studies.
2.3.3. Hormone assays
Plasma levels of LH and FSH (Tg2576 mice) were assayed by radioimmunoassay at
the National Hormone and Peptide Program (Torrance, CA).
Fig. 1. Quantitation of Evan's blue extravasation. Female B6/SJL mice were either
ovariectomized (n=5) or left intact (n=5). Two weeks after surgery mice were injected
with a 2% Evan's blue dye solution to examine BBB permeability. There was a 2.2-fold
increase in Evan's blue dye extravasation into the brains of ovariectomized female mice
compared to control (mean±SEM, Pb0.05).
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Parafﬁn embedded and methacarn ﬁxed brain hemispheres were serially sectioned
(8 µm in thickness) in the sagittal planewith a Leica CA 1900 cryostat. The sections were
deparafﬁnized with xylene and hydrated through 100%, 95%, 70%, and 50% ethanol for
5 min in each, and then incubated in Tris-buffered saline (TBS) for 10 min. Endogenous
peroxidase activity was eliminated with a 30 min incubation in 3% H2O2 in methanol.
Following placement of the sections in citrate buffer (1 mM, pH 6.0), slides were
autoclaved at 121 °C for 30 min and then rinsed well. Non-speciﬁc binding sites were
blocked with 10% normal goat serum (NGS) in TBS for 30 min before application of anti-
connexin-43 rabbit polyclonal antibody (1:100 dilution, Cell Signaling Technologies,
Danvers, MA) overnight at 4 °C. After a series of washes, tissue sections were incubated
with both the goat afﬁnity puriﬁed antibody to rabbit IgG (1:50 dilution, 30 min) and
the rabbit PAP (1:250 dilution, 60 min). Immunostaining was then developed using
diaminobenzidine (DAKO Corporation, Carpinterie, CA) for 10 min, slides mounted
using Permount (Fisher Chemicals, Fair Lawn, NJ) and staining analyzed under an
inverted microscope (Zeiss Axiophot, Thornwood, NY). For ZO-1, an anti-ZO-1 rabbit
polyclonal antibody (1:50 dilution; Invitrogen, Carlsbad, CA) was applied overnight at
4 °C, followed by washes as described above and immunoﬂuorescent detection using a
goat-anti rabbit IgG antibody conjugated to ﬂuorescein isothiocyanate (FITC; Santa Cruz
Biotechnologies, Santa Cruz, CA; 1:100 dilution, 2 h). To control for non-speciﬁc
secondary antibody binding, control tissue sections were treated with secondary
antibody alone.
2.3.5. Immunoblot analyses
The cerebral part of the frozen hemisphere of themouse brainwas homogenized on
ice in lysis buffer (20 mmol/l Tris–HCl, pH 7.6, 150mmol/l NaCl, 1 mmol/l EDTA,1mmol/
l EGTA,1% sodium dodecyl sulfate (SDS), and protease inhibitor cocktail (Sigma-Aldrich,
St. Louis, MO), and then centrifuged for 10 min at 10 000 g at 4 °C. Following protein
assay (Bicinchoninic Acid Protein assay kit; Pierce, Rockford, IL, USA), equal amounts of
protein were loaded onto 10–20% tricine gels (Invitrogen, Carlsbad, CA) for SDS-
polyacrylamide gel electrophoresis, transferred to polyvinylidene diﬂuoride mem-
branes (Bio-Rad Laboratories, Hercules, CA, USA). The membrane was ﬁxed with
glutaraldehyde (4%, v/v in TBST for 30 min), blocked with milk (10%, w/v in TBST for 2 h)
and then probed with a rabbit polyclonal antibody against Cx43 (dilution 1:1000, Cell
Signaling Technologies, Danvers, MA) or GAPDH (dilution 1:1000, Santa Cruz
Biotechnologies, Santa Cruz, CA) overnight at 4 °C. The blot was then incubated with
the corresponding horseradish peroxidase conjugated secondary antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) for 1 h at 22 °C, washed and developed with
enhanced chemiluminescence reagent (Santa Cruz Biotechnology, Santa Cruz, CA) as
per the manufacturer's instructions. The chemiluminescent signal was captured on
autoradiographs (Eastman Kodak, Rochester, NY, USA), which were scanned and the
intensity of the autoradiograph signals (including a blank region) was determined using
the NIH Image J Software. Control and treatment values were corrected for blank values,
normalized to their respective GAPDH band intensity and the results then expressed as
a fold change over sham levels.
2.4. Statistical analyses
ANOVA analyses and Student's t-tests were used to assess statistically signiﬁcant
differences between treatment groups.
3. Results
To assess the role of reproductive hormones in the maintenance of
the BBB, young mice were ovariectomized and 2 weeks later the
animals were injected with Evan's blue dye and the brains were
removed for analysis. A 2.2-fold increase in Evan's blue dye extra-
vasation into the brains of ovariectomized female mice compared to
controls was noted (Fig. 1).
The ovariectomy-induced changes in the selective permeability of
the BBB may result from increases in paracellular permeability due to
changes in tight or gap junction proteins of microvessels. To examine
whether gap proteins involved in the maintenance of the BBB were
altered following ovariectomy, we examined the microvasculature for
alterations in the staining of Cx43. There was a clear redistribution of
the Cx43 labeling of themicrovascular endothelium in ovariectomized
compared with control animals (Fig. 2). Staining was clearly evident
along the extracellular endothelium of microvessels in the cortex of
the brain. However, following ovariectomy, there was a redistribution
of immunoreactivity from the endothelium to speciﬁc endothelial
cells. This ovariectomy-induced partitioning of Cx43 may alter
endothelial barrier function, and thus the permeability of the BBB.
Since ovariectomy decreases serum estradiol but markedly
increases serum gonadotropins levels in mice [39,40], these results
suggest that hormonal changes associated with ovariectomy alter thebiophysical characteristics of the BBB. To distinguish betweenwhether
the decline in serum sex steroids or the increase in gonadotropins was
responsible for alterations in gap junction proteins that maintain the
integrity of the BBB, mice were sham operated, ovariectomized (low
estradiol, high gonadotropins) or ovariectomized and treated with the
GnRH agonist leuprolide acetate (low estradiol, low gonadotropins).
To conﬁrm that ovariectomy and leuprolide acetate treatments
modulated blood sex hormone levels, plasma collected from mice at
0, 1, 3 and 9 months (and also 6 months for vehicle and leuprolide-
treated groups) post-treatment were analyzed for LH and FSH
concentrations. The concentration of plasma LH increased 2.2-fold
between 7 and 16 months of age in sham ovariectomized animals
(0.44±0.11 ng/ml vs 0.96±0.07 ng/ml, respectively; mean±SEM,
Pb0.05, n=9). Ovariectomy induced an 8.4-fold increase in the
concentration of plasma LH by 9 months post-surgery (16 months of
age) compared to time 0 (7 months of age; 0.59±0.08 ng/ml vs 4.92±
0.65 ng/ml, respectively; Pb0.001, n=9). Leuprolide acetate treat-
ment of ovariectomized mice completely suppressed the increase in
the concentration of plasma LH from 1 month post-treatment to
9 months post-treatment (0.54±0.09 ng/ml vs 0.70±0.05 ng/ml; ns,
n=9). Likewise, the concentration of plasma FSH did not alter
signiﬁcantly between 0 and 9 months post-surgery in sham
ovariectomized mice, (7.8±2.2 ng/ml vs 12.9±2.2 ng/ml; n=6).
Ovariectomy induced a signiﬁcant 10.9-fold increase in the concen-
tration of plasma FSH from 4.8±1.0 ng/ml pre-surgery to 52.6±3.1 ng/
ml (Pb0.05, n=6) at 1 month post-surgery and the concentration of
plasma FSH remained at this level to 9 months post-surgery.
Leuprolide acetate treatment of mice that were ovariectomized
suppressed the increase in plasma FSH at 1 month (16.2±1.9 ng/ml;
n=6) and FSH remained around sham ovariectomy levels through to
9 months post-surgery (8.4±1.0 ng/ml; n=6). Overall, these results
indicate that leuprolide acetate suppresses plasma LH and FSH, and
that the ovariectomy induced increases in plasma LH and FSH is
suppressed by leuprolide acetate.
To examine how differences in sex steroids and gonadotropins affect
the integrity of the BBB, we next examined the expression of the gap
junctionprotein Cx43.An increase in total Cx43 expressionwasobserved
in themouse brain following ovariectomy (low serum sex steroids, high
serum gonadotropins) compared to sham-operated controls (Fig. 3),
while a signiﬁcant decrease in Cx43 expression was observed in
ovariectomized mice that were treated with leuprolide acetate (low
serum sex steroids and gonadotropins). The decrease in Cx43 expression
following leuprolide acetate treatment suggests that gonadotropins
(Figs. 2 and 3), and not sex steroids regulate Cx43 expression.
To examine whether reproductive hormones also altered the
distribution of tight junction proteins, we probed tissue sections
with a polyclonal antibody against ZO-1, a cytoplasmic membrane-
Fig. 3. Gonadotropins modulate the brain expression of connexin-43. Immunoblots of
homogenized brain tissue samples from control (sham operated), ovariectomized, and
ovariectomized and leuprolide acetate-treated Tg2576 mice (n=4 each) were probed
with the polyclonal connexin-43 polyclonal antibody used in Fig. 2. The expression of
connexin-43 increased following ovariectomy (low sex steroids, high gonadotropins)
but decreased to sham levels when treated with leuprolide acetate (low sex steroids,
low gonadotropins), indicating that changes in the serum gonadotropins, and not the
sex steroids, regulate Cx43 expression (mean±SEM, Pb0.05).
Fig. 2. Ovariectomy alters the immunolocalization of the gap junction protein connexin-43 in cortical microvessels. Ovariectomized and control brain sections were im-
munocytochemically labeled with a rabbit polyclonal antibody against connexin-43. Results indicated a clear redistribution of the Cx43 labeling of the microvascular endothelium in
ovariectomized compared with control animals. Two representative control sections are shown on the left (#27 and #29) and 2 representative ovariectomized brain sections are
shown on the right (#16 and #17). All pictures are shown at objective magniﬁcation 63×.
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stability of tight junctions. At objective magniﬁcations of 40× and 63×,
no differences in ZO-1 localization were observed between OVX mice
and controls using immunoﬂuorescence (Fig. 4) or diaminobenzidine
staining (data not shown). To examine whether reproductive hor-
mones also altered the expression of ZO-1, we immunoprobed the blot
described in Fig. 3. Immunoblot analyses of the 225 kDa ZO-1 band
indicated no change in expression between the sham, ovariectomized,
and ovariectomized and leuprolide acetate-treated groups (Fig. 5)
suggesting that reproductive hormones do not alter ZO-1 expression
and distribution.
4. Discussion
The selective permeability of the BBB is maintained by complex
junctional interactions between endothelial cells of brain capillaries
[41–43]. While this selective permeability normally excludes the
passage of molecules ≥100 Da, our results indicate that ovariectomy
alters the selective permeabilityof theBBB, allowingmolecules≥961Da,
the molecular mass of Evan's blue dye, to cross the BBB (Fig. 1). At the
molecular level, we observed no change in the expression of the tight
junction protein ZO-1 (Figs. 4 and 5), suggesting that the abrupt
Fig. 4. Reproductive hormones do not alter cortical microvessel ZO-1 localization. Ovariectomized (#17) and control (#27) brain sections were immunoﬂuorescently labeled with a
rabbit polyclonal antibody against ZO-1. No differences in ZO-1 localization were observed between ovariectomized and control mice. All pictures are shown at objective
magniﬁcation 40×. Non-speciﬁc staining of pyramidal neurons also was detected (not shown).
Fig. 5. Reproductive hormones do not alter brain ZO-1 expression. Immunoblots from
Fig. 3wereprobedwith the ZO-1 polyclonal antibody used in Fig. 4. Nodifference in ZO-1
expression was detected between groups (mean±SEM, n=4, ns.
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changes in the expression and/or distribution of other junctional
proteins. Indeed, we observed both a redistribution and increase in
the expression of the gap junction protein Cx43 following ovariectomy
(Figs. 2 and 3), supporting previous research that Cx43 may inﬂuence
endothelial barrier function [2]. Whether the increase in Cx43
expression is a protective response to the ovariectomy-induceddecrease
in selective permeability requires further research. Irrespective, the
redistribution of Cx43 expression in ovariectomized animals potentially
increases paracellular pathway diffusion, and also likely alters both the
electrical communication and the free diffusion of molecules and ions,
including small intracellular signaling molecules, between cells. Such
changes may be the biochemical underpinning of the morphological
changes observed in the cerebrovasculature with aging.
Our experimental paradigm manipulating reproductive hormones
of the hypothalamic–pituitary–gonadal axis using ovariectomy and
leuprolide acetate indicated that gonadotropins weremore likely than
sex steroids to modulate the expression of the Cx43 gap junction
protein and its distribution (Figs. 2 and 3), consistent with previous
studies in other systems demonstrating that reproductive hormones
modulate Cx43 expression [14–23]. Alterations in vascular integrity
appear to result from the LH-induced phosphorylation/dephosphor-
ylation and down-regulation of Cx43 expression [14–18] in the
endothelium, mediated via LH/hCG receptors during increases in
gonadotropin concentration. The functionality of endothelial LH/hCG
receptors in mediating barrier integrity has been demonstrated in the
uterus where hCG administration decreases vascular resistance and
plays a role in the peri-implantation period by increasing uterine
blood ﬂow through vasodilation [32]. Since LH can cross the BBB [44]
and LH is expressed by [45], and accumulates intracellularly in the
pyramidal neurons of AD compared with age-matched control brains
[46], neural LH expression might inﬂuence Cx43 expression/distribu-
tion around astrocytes, microglia and neurons. FSH also has been
shown to up-regulate Cx43 expression [18], and also could possibly
induce vascular changes in the BBB.
While our studies suggest that gonadotropins are important for
changes in Cx43, it is possible that changes to the BBB aremediated by
the decline in sex steroids via other mechanisms. Support for this
notion is indicated by the ﬁndings that progesterone promotes the
reconstitution of the BBB after traumatic brain injury (reviewed in
[47]). Likewise, 17β-estradiol has been shown to modulate the ex-
pression of occludin, transendothelial resistance and paracellular
permeability in human vascular endothelial cells [25] and human
cervical epithelial cells [26].It is possible that GnRH also modulates Cx43 expression or
localization [48] since ovariectomy greatly increases GnRH secretion
[49,50]. In this connection, a rare complication fromthe administration
of GnRH agonists to men for the treatment of prostate cancer is
pituitary apoplexy [51,52], a hemorrhage of a subclinical pituitary
adenoma resulting in acute symptoms of headache, vomiting,
meningismus, visual impairments such as diplopia from opthalmo-
plegia, hormone dysfunction and alterations of consciousness. These
symptoms appearwithin hours of GnRH agonist administrationduring
the increase in serum gonadotropins [53], and suggest that either
gonadotropins or GnRH signaling alters vascular integrity. Cx43 has
been immunolocalized to gap junctions in the pituitary [54].
AD is characterized by a chronic inﬂammatory response that is
suggestive of alterations in BBB integrity. While the etiology of AD
neuroinﬂammation is unclear, it is known that experimental induc-
tion of brain inﬂammation by injection of complete Freund's adjuvant
into the right plantar hindpaw in female Sprague–Dawley rats
increases BBB permeability as determined by sucrose uptake and
major changes in junctional protein expression (−60% occludin, 450%
claudin-3, and 615% claudin-5; [55]). In AD, where serum LH/FSH
levels are elevated compared with age-matched control individuals
[56,57], Cx43 immunoreactivity is elevated in cortical areas containing
Aβ plaques, and Cx43 is localized to astrocytic gap junctions in AD
brain [58]. These results are consistent with the increases in Cx43
observed in our study following ovariectomy (Fig. 3). In this
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pathway [37] and its deposition in the vasculature has been postulated
to be a vascular sealant [11,59,60]. Whether LH induces neuroin-
ﬂammation via alteration of the BBB remains to be tested.
Tight junctions are well known to change in the mammary gland
from ‘leaky’ during pregnancy to ‘tight’ at the commencement of
lactation [61,62]. Physiological and ultrastructural evidence [61,63]
supports the concept that the junctional complexes of the secretory
epithelium change from ‘leaky’ to ‘tight’ at parturition. Birth is of
course associated with a marked reduction in progesterone and hCG,
the fetal equivalent of LH that binds the same receptor, providing
further support for a role of gonadotropins and/or sex steroids in
modulating the BBB. In this respect, maturation of tight junctions as
indicated by the direct analysis of the cleft index of individual
junctions has been reported during development [64,65].
In the ovary, the LH surge is thought to interrupt cell-to-cell
communication within the ovarian follicle, leading to a decrease in
intraoocyte concentrations of cAMP followed by resumption of
meiosis [66]. The gonadotropin-induced redistribution of Cx43 (Fig.
2) is consistent with an interruption of cell-to-cell communication,
and intriguingly, LH has been postulated to promote the aberrant re-
entry of neurons into the cell cycle in AD [67]. Thus, elevated LH levels
with menopause/andropause may alter Cx43 expression and redis-
tribution required to initiate cell division. In this respect, transfection
expression of the Cx43 gene has been shown to induce E-cadherin
overexpression and an inhibition of LH(7) cell proliferation indicating
a signiﬁcant role of Cx43 in the regulation of cell proliferation [68].
Thus, our results indicate that change in reproductive hormone
signaling following ovariectomy induces an increase in the expression
and relocalization of endothelial Cx43 that is accompanied by an in-
crease in the permeability of the BBB. Given that ovariectomy induces
changes in reproductive hormones similar to that of menopause/
andropause, these data suggest that reproductive hormones regulate
the selective permeability of the BBB via changes in junctional pro-
teins. The exact compliment of junctional proteins altered by repro-
ductive hormones awaits further study. These results have important
implications for explaining changes in the BBBwith aging [69–71], and
in the development of the pathophysiology of age-related neu-
rodegenerative/neuroinﬂammatory diseases such as stroke and AD
[72,73].
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